Skip to main content
Premium Trial:

Request an Annual Quote

In Shift to Drugs after Ocimum Deal, Gene Logic Plans Name Change

NEW YORK (GenomeWeb News) - Gene Logic said today it plans to change its name to Ore Pharmaceuticals in order to better express its drug repositioning identity now that it has agreed to sell its genomics business to Ocimum Biosolutions.
The company said two weeks ago it plans to sell its genomics assets to Ocimum for $10 million as it completes its restructuring into the pharmaceuticals field.
Gene Logic said the new name has been approved by the board of directors and now awaits shareholder approval. The company also is waiting for the shareholders' nod to proceed with its proposed sale to Ocimum.
Gene Logic said it will shift ownership of its name to Ocimum when the deal closes.
“We believe that the Gene Logic name is a valuable brand that appropriately should remain with the genomics business of Ocimum Biosolutions," Gene Logic CEO Charles Dimmler said in a statement.
The company said it is currently collaborating with eight pharmaceutical companies to reposition some of their compounds. The pharma partners include Abbott, H. Lundbeck, Merck Serono, Organon, Pfizer, Roche, and Solvay.
Gene Logic also said its technology program includes the use of its own genomic and toxicogenomic databases, for which it will hold full and exclusive rights to use in its repositioning business.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.